GSK plc GLAXF OTC

Other OTC • Healthcare • Drug Manufacturers - General • GB • USD

SharesGrow Score

72/100

4/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

GSK plc (GLAXF) reported total assets of $61.11B and total liabilities of $45.09B for fiscal year 2025, resulting in total equity of $15.95B.

The company held $3.41B in cash and short-term investments. Total debt stood at $17.72B, with net debt of $14.32B. The Debt-to-Equity (D/E) ratio was 1.11 (moderate).

Current ratio is 0.82, which may signal tight short-term liquidity. Interest coverage is 10.2x (strong).

Criteria supported by this page:

HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
MOAT (90/100) — Total assets $61.11B and equity $15.95B support the company's competitive scale
VALUE (75/100) — Debt-to-Equity 1.11 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 70/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score

72/100

SG Score

View full scorecard →

✓

VALUE

75/100

Price-to-Earnings & upside

→ Valuation

—

FUTURE

N/A

No coverage

✓

PAST

100/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

Proven by this page

✓

MOAT

90/100

→ Income

GROWTH

45/100

→ Income

✓

INCOME

70/100

→ Income

GSK plc Balance Sheet History

Metric	FY2025	FY2024	FY2023	FY2022
Total Assets	$61.11B	$59.46B	$59.01B	$60.15B
Total Liabilities	$45.09B	$46.38B	$46.21B	$50.05B
Total Debt	$17.72B	$16.99B	$18.02B	$20.99B
Cash & Investments	$3.41B	$3.71B	$5.18B	$7.88B
Total Stockholders Equity	$16.37B	$13.67B	$13.35B	$10.6B